

HEALTHCARE MONTHLY

DECEMBER 2022

Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics **Medical Devices**



ACQUIROR

ACQUISITION SYNOPSIS





- · Werfen Life Group SA has reached an agreement to acquire Immucor, Inc.
- Immucor, a portfolio company of TPG, is a U.S.-based provider of transfusion and transplantation diagnostic products worldwide
- Werfen is a Spain-based manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells and data management solutions for use primarily in hospitals and independent clinical laboratories
- Total Consideration: \$2.0 billion



BioTech / Pharma



- · Merck & Co., Inc. (NYSE:MRK) has reached an agreement to acquire Imago BioSciences, Inc. (NASDAQ:IMGO)
- · Imago BioSciences is a clinical stage biopharmaceutical company that develops new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases
- Merck is a global healthcare company focused on delivering healthcare solutions through prescription medicines, vaccines, biologic therapies, animal health and consumer care products
- Total Consideration: \$1.4 billion
- Per share price represents a premium of ~106%







- **EVERNORTH**.
- · VillageMD, majority owned by Walgreens Boots Alliance (NASDAQ:WBA), has reached a definitive agreement to acquire Summit Health-CityMD
- Summit Health, a portfolio company of Warburg Pincus, is a leading provider of primary, specialty and urgent care services
- · VillageMD provides healthcare management services for primary care physicians
- · Walgreens Boots Alliance is an integrated healthcare, pharmacy and retail leader
- Evernorth Care Group, Cigna Corp's (NYSE:CI) health services organization that creates and connects benefits, pharmacy and care solutions, will invest \$2.5 billion acquiring a minority stake in VillageMD
- Total Consideration: \$8.9 billion, consisting of \$7.0 billion in equity and \$1.9 billion in debt






- · Evolent Health (NYSE:EVH) has reached a definitive agreement to acquire National Imaging Associates, Inc. from Centene Corp.
- · National Imaging Associates provides radiology benefits management services offering advanced imaging, automated prior authorization, cardiac solutions, musculoskeletal management and physical medicine services
- · Evolent Health provides healthcare delivery and payment solutions
- Total Consideration: \$800 million, consisting of \$400 million in cash, \$250 million in common shares and \$150 million in earnout




HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Neogene Therapeutics, Inc.	AstraZeneca (LSE:AZN)	Neogene Therapeutics discovers, develops and manufactures next-generation T-cell receptor therapies that offer a novel cell therapy approach for targeting cancer Total Consideration: \$320 million, consisting of \$200 million in cash and \$120 million in earnout
Oyster Point Pharma, Inc. (NASDAQ:OYST)	Viatris, Inc. (NASDAQ:VTRS)	Oyster Point Pharma discovers, develops and commercializes first-in-class pharmaceutical therapies to treat ophthalmic diseases Total Consideration: \$317 million Per share price represents a premium of ~39%
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)	Indivior PIc (LSE:INDV)	Opiant Pharmaceuticals develops treatments for addiction and drug overdose using intranasal and injectable delivery technologies, such as its NARCAN Nasal Spray Total Consideration: \$210 million, consisting of ~\$145 million in cash and \$65 million in earnout Per share price represents a premium of ~111%


Target	Acquiror	Life Sci / Diagnostics Transactions
Famy Life Sciences Pvt. Ltd. (Taparia Tools)	Viatris, Inc. (NASDAQ:VTRS)	Famy Life Sciences is a drug development platform that identifies and develops clinical stage assets in unmet areas for ophthalmology, oncology and dermatology Total Consideration: ~\$300 million
MGC Diagnostics Holdings, Inc. (Altus Capital Partners)	Caire, Inc. (NGK Spark Plug)	MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems for detecting, classifying and managing cardiorespiratory disease Total Consideration: \$170 million
Gateway Genomics, LLC	Myriad Genetics, Inc. (NASDAQ:MYGN)	Gateway Genomics is a personal genomics company that develops consumer genetic tests including the top selling SneakPeek Early Gender DNA test Total Consideration: \$100 million, consisting of \$67.5 million in cash and \$32.5 million in earnout

Selected TM Capital Healthcare Experience









larget	Acquiror	Medical Device Transactions
Apollo Endosurgery, Inc. (NASDAQ:APEN)	Boston Scientific Corp. (NYSE:BSX)	Apollo Endosurgery develops minimally invasive devices used during endoluminal surgery procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss Total Consideration: \$615 million Per share price represents a premium of ~67%
Alpha Manufacturing &	ARCH Medical Solutions Corp.	Alpha Manufacturing & Design manufactures and supplies surgical instruments, drill bits and reamers,

Design, LLC (The Jordan Company)

supplies surgical instruments, drill bits and reamers blades and implants, providing medical OEMs with engineered and complex surgical devices

Excel Scientific
LLC (Vance Street
Capital)

Innovize is an advanced medical contract manufacturer focused on complex materials conversion for critical components of diagnostics, wearables and electronics-focused devices from the initial design to the prototype and final product

TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



John Dean Principal jdean@tmcapital.com 404.995.6234



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



Steve Hunter

Managing Director, Sponsor Coverage
shunter@tmcapital.com
404.995.6232



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com

